1500 Participants Needed

AI Detection for Cardiovascular Disease Prevention

(AI INFORM Trial)

Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Brigham and Women's Hospital
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

AI INFORM is a multicenter randomized trial that will test the hypothesis that providing clinicians information on the presence and amount of coronary artery calcifications (CAC), will result in initiation or intensification of preventive therapies. The study will use a cloud-based artificial intelligence (AI) platform (Nanox.AI) that can analyze non contrast chest CT and estimate the amount of CAC.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment Nanox.AI Coronary Artery Calcification Assessment for cardiovascular disease prevention?

Research shows that AI-based systems can automatically and accurately measure coronary artery calcium, which is a strong predictor of heart-related events. This automated approach is efficient and correlates well with manual methods, suggesting it could help in early detection and prevention of cardiovascular diseases.12345

Is the AI Detection for Cardiovascular Disease Prevention safe for humans?

The research articles focus on the accuracy and reliability of AI systems in detecting coronary calcifications using CT scans, but they do not provide specific safety data for human use of the AI technology itself.46789

How does the AI-based treatment for cardiovascular disease prevention differ from other treatments?

This AI-based treatment is unique because it uses artificial intelligence to automatically detect and quantify coronary artery calcium from CT scans, which helps in assessing the risk of cardiovascular disease more efficiently and accurately compared to traditional methods that rely on manual analysis.125910

Eligibility Criteria

This trial is for individuals aged 40-75 who've had a chest CT scan in the last 3 years and have no history of coronary artery disease, cancer, or any other life-limiting conditions. It's aimed at enhancing cardiovascular disease prevention.

Inclusion Criteria

I am between 40-75 years old and had a chest CT scan in the last 3 years.

Exclusion Criteria

I do not have any other condition that could shorten my life.
I have had heart disease related to my arteries.
I have had cancer before.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Notification or non-notification of coronary artery calcification detected by AI, followed by recommendation or non-recommendation of preventive therapy

6 months

Follow-up

Participants are monitored for changes in LDL-C, initiation or intensification of preventive therapies, and occurrence of cardiovascular events

12 months

Treatment Details

Interventions

  • Nanox.AI Coronary Artery Calcification Assessment
Trial OverviewThe AI INFORM study is testing if notifying clinicians about the presence and amount of calcium buildup in arteries using an AI tool (Nanox.AI) leads to better preventive care. This involves analyzing past chest CT scans without contrast.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Notification of Coronary Artery CalcificationExperimental Treatment1 Intervention
Notification to providers of the presence of coronary artery calcification automatically detected by AI based device (software) on chest CT. Recommendation of preventive therapy.
Group II: Non-notification of Coronary Artery CalcificationActive Control1 Intervention
No notification to providers of the presence of coronary artery calcification on chest CT automatically detected by AI based device (software) on chest CT. No recommendation of preventive therapy.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Brigham and Women's Hospital

Lead Sponsor

Trials
1,694
Recruited
14,790,000+

Nano-X Imaging Limited

Collaborator

Trials
1
Recruited
1,500+

Findings from Research

The AI-based automatic coronary artery calcium (CAC) scoring software demonstrated excellent correlation and agreement with a semi-automatic method, with a Spearman correlation coefficient of 0.935 for Agatston score, indicating high reliability in measuring coronary artery health.
The automatic software was significantly faster, taking a median of 36 seconds compared to 59 seconds for the semi-automatic method, making it a more efficient option for clinical use in assessing cardiovascular risk.
Evaluation of an AI-based, automatic coronary artery calcium scoring software.Sandstedt, M., Henriksson, L., Janzon, M., et al.[2021]
The gradient boosting machine (GBM) model demonstrated a remarkable sensitivity of 100% for predicting obstructive coronary artery disease (CAD) in a study of 435 patients, indicating it can effectively rule out the disease.
While the model showed high negative predictive value (100%), its positive predictive value was lower at 38%, suggesting that while it is excellent at identifying patients without CAD, it may not be as reliable in confirming the presence of the disease.
Machine Learning-based Algorithm Enables the Exclusion of Obstructive Coronary Artery Disease in the Patients Who Underwent Coronary Artery Calcium Scoring.Głowacki, J., Krysiński, M., Czaja-Ziółkowska, M., et al.[2020]
An AI-based automatic coronary artery calcium (CAC) scoring system demonstrated excellent reliability when compared to manual scoring in low-dose chest CT scans, with a high intraclass correlation coefficient (0.989) across a study of 452 subjects from three institutions.
While the AI system showed good performance overall, the reliability of CAC severity categorization varied among different datasets, indicating that results may differ based on the institution's imaging quality and conditions.
Fully automatic coronary calcium scoring in non-ECG-gated low-dose chest CT: comparison with ECG-gated cardiac CT.Suh, YJ., Kim, C., Lee, JG., et al.[2023]

References

Evaluation of an AI-based, automatic coronary artery calcium scoring software. [2021]
Machine Learning-based Algorithm Enables the Exclusion of Obstructive Coronary Artery Disease in the Patients Who Underwent Coronary Artery Calcium Scoring. [2020]
Fully automatic coronary calcium scoring in non-ECG-gated low-dose chest CT: comparison with ECG-gated cardiac CT. [2023]
Deep convolutional neural networks to predict cardiovascular risk from computed tomography. [2022]
Fully automated coronary artery calcium quantification on electrocardiogram-gated non-contrast cardiac computed tomography using deep-learning with novel Heart-labelling method. [2023]
Detection of heart calcification with electron beam CT: interobserver and intraobserver reliability for scoring quantification. [2016]
[Detection and quantification of coronary calcification: an update]. [2016]
Automatic Calcium Scoring in Low-Dose Chest CT Using Deep Neural Networks With Dilated Convolutions. [2019]
Detection of coronary calcifications from computed tomography scans for automated risk assessment of coronary artery disease. [2019]
Evaluation of an artificial intelligence coronary artery calcium scoring model from computed tomography. [2023]